176 related articles for article (PubMed ID: 1702566)
21. Rapid rise of serum testosterone following discontinuation of long term treatment of prostate carcinoma with an LHRH-agonist.
Kreis W; Budman DR; Delli Bovi P; Vinciguerra V
Onkologie; 1988 Dec; 11(6):292-3. PubMed ID: 2977219
[No Abstract] [Full Text] [Related]
22. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
Garnick MB; Mottet N
BJU Int; 2012 Aug; 110(4):499-504. PubMed ID: 22093775
[TBL] [Abstract][Full Text] [Related]
23. Rat prostatic weight regression in reaction to ketoconazole, cyproterone acetate, and RU 23908 as adjuncts to a depot formulation of gonadotropin-releasing hormone analogue.
Lamberts SW; Uitterlinden P; de Jong FH
Cancer Res; 1988 Nov; 48(21):6063-8. PubMed ID: 2844399
[TBL] [Abstract][Full Text] [Related]
24. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.
Seidenfeld J; Samson DJ; Aronson N; Albertson PC; Bayoumi AM; Bennett C; Brown A; Garber A; Gere M; Hasselblad V; Wilt T; Ziegler K
Evid Rep Technol Assess (Summ); 1999 May; (4):i-x, 1-246, I1-36, passim. PubMed ID: 11098244
[TBL] [Abstract][Full Text] [Related]
25. Treatment of patients with advanced cancer of the prostate: phase III trial, zoladex against castration; a study of the British Prostate Group.
Turkes AO; Peeling WB; Griffiths K
J Steroid Biochem; 1987; 27(1-3):543-9. PubMed ID: 2961938
[TBL] [Abstract][Full Text] [Related]
26. [Value of a LHRH agonist (Zoladex) in hormonotherapy of advanced cancers of the prostate. Apropos of 22 patients].
Bourgne N; Audhuy B; Kohser F; Levin G
Rev Med Interne; 1987; 8(3):325-30. PubMed ID: 2956658
[TBL] [Abstract][Full Text] [Related]
27. Influence of continuous luteinizing hormone-releasing hormone agonist treatment on steroidogenic enzymes in the human testis.
Petersson F; Hammar M; Mathson K; Hjertberg H; Varenhorst E
Scand J Urol Nephrol; 1987; 21(4):267-71. PubMed ID: 2965409
[TBL] [Abstract][Full Text] [Related]
28. Long-term therapy with a depot luteinizing hormone-releasing hormone analogue (Zoladex) in patients with advanced prostatic carcinoma.
Debruyne FM; Denis L; Lunglmayer G; Mahler C; Newling DW; Richards B; Robinson MR; Smith PH; Weil EH; Whelan P
J Urol; 1988 Oct; 140(4):775-7. PubMed ID: 2971119
[TBL] [Abstract][Full Text] [Related]
29. Testosterone Suppression with Luteinizing Hormone-Releasing Hormone (LHRH) Agonists in Patients Receiving Radiotherapy for Prostate Cancer.
Wilke D; Patil N; Hollenhorst H; Bowes D; Rutledge R; Ago C
Pharmacotherapy; 2018 Mar; 38(3):327-333. PubMed ID: 29337395
[TBL] [Abstract][Full Text] [Related]
30. Re: Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. A. V. Kaisary et al. Br. J. Urol., 67, 502-508, 1991.
Bunce C
Br J Urol; 1992 Apr; 69(4):441-2. PubMed ID: 1533812
[No Abstract] [Full Text] [Related]
31. A comparison between surgical orchidectomy and LH-RH analogue ('Zoladex', ICI 118,630) in the treatment of advanced prostatic carcinoma--a multi-centre clinical study.
Kaisary AV; Ryan PG; Turkes A; Peeling WB; Griffiths K
Prog Clin Biol Res; 1988; 260():89-100. PubMed ID: 2966408
[No Abstract] [Full Text] [Related]
32. 3-month formulation of goserelin acetate ('Zoladex' 10.8-mg depot) in advanced prostate cancer: results from an Italian, open, multicenter trial.
Fontana D; Mari M; Martinelli A; Boccafoschi C; Magno C; Turriziani M; Maymone SS; Cunico SC; Zanollo A; Montagna G; Frongia M; Jacobellis U
Urol Int; 2003; 70(4):316-20. PubMed ID: 12740498
[TBL] [Abstract][Full Text] [Related]
33. A new longer-acting LHRH analog depot: preliminary results of a Dutch open phase II clinical study on a 10.8 mg Zoladex 3-monthly depot.
Dijkman GA; Fernandez del Moral P; Plasman JW; Pull HC; van der Meijden AP; Debruyne FM; Hutchinson FG; Furr BJ
Eur Urol; 1990; 18 Suppl 3():22-5. PubMed ID: 2151271
[TBL] [Abstract][Full Text] [Related]
34. Biochemical monitoring of carcinoma of prostate treated with an LH-RH analogue (Zoladex).
Siddall JK; Hetherington JW; Cooper EH; Newling DW; Robinson MR; Richards B; Denis L
Br J Urol; 1986 Dec; 58(6):676-82. PubMed ID: 2432985
[TBL] [Abstract][Full Text] [Related]
35. Luteinizing hormone-releasing hormone agonists in prostate cancer. Elimination of flare reaction by pretreatment with cyproterone acetate and low-dose diethylstilbestrol.
Bruchovsky N; Goldenberg SL; Akakura K; Rennie PS
Cancer; 1993 Sep; 72(5):1685-91. PubMed ID: 7688656
[TBL] [Abstract][Full Text] [Related]
36. Effect of long-acting LHRH analog (Zoladex) on prostate cancer: evaluated by transrectal ultrasonography.
Drago JR; Nesbitt JA; Cirulli C
Urology; 1988 Oct; 32(4):285-7. PubMed ID: 2972104
[TBL] [Abstract][Full Text] [Related]
37. Prolactin and pituitary gonadotropin values and responses to acute luteinizing hormone-releasing hormone (LHRH) challenge in patients having long-term treatment with a depot LHRH analogue.
Mahler C; Verhelst J; Chaban M; Denis L
Cancer; 1991 Feb; 67(3):557-9. PubMed ID: 1824680
[TBL] [Abstract][Full Text] [Related]
38. The role of prostate specific antigen in the baseline assessment of patients undergoing hormone therapy for advanced prostate cancer.
Emtage LA; Lewis PW; Blackledge GR
Br J Urol; 1987 Dec; 60(6):572-7. PubMed ID: 2447997
[TBL] [Abstract][Full Text] [Related]
39. Treatment of patients with advanced cancer of the prostate using a slow-release (depot) formulation of the LHRH agonist ICI 118630 (Zoladex).
Walker KJ; Turkes AO; Turkes A; Zwink R; Beacock C; Buck AC; Peeling WB; Griffiths K
J Endocrinol; 1984 Nov; 103(2):R1-4. PubMed ID: 6238116
[TBL] [Abstract][Full Text] [Related]
40. Luteinizing hormone-releasing hormone (LHRH) agonists for treatment of advanced prostatic carcinoma.
Chodak GW
Urology; 1989 May; 33(5 Suppl):42-4. PubMed ID: 2523610
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]